The desk / continuation
Dispatches 205–215 of 476; page 18 of 40.
A comprehensive clinical and harm-reduction guide to Ketamine in India, exploring its NMDA-receptor antagonism, its classification as a Schedule X/NDPS psychotropic, Jan Aushadhi pricing, the 'K-Hole' phenomenon, and the 2026 club drug trends.
GeneralA comprehensive clinical and harm-reduction guide to Dextromethorphan (DXM) in India, exploring its NMDA-receptor antagonism, the four plateaus of dissociation, Jan Aushadhi pricing, and the 2026 CDSCO crackdown on cough syrup misuse.
GeneralA comprehensive clinical and harm-reduction guide to Nitrous Oxide (N2O) in India, exploring its NMDA-receptor antagonism, the hidden risk of permanent nerve damage, Jan Aushadhi (Institutional) pricing, and the 2026 'Whippet' party drug trend.
GeneralA comprehensive clinical and harm-reduction guide to Promethazine (Phenergan) in India, exploring its dopamine-blocking mechanism, its role in the 'Lean' cocktail, Jan Aushadhi pricing, and the risk of acute dystonia as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Diphenhydramine (Benadryl) in India, exploring its anticholinergic mechanism, the 'Hatman' deliriant phenomenon, Jan Aushadhi pricing, and the risk of early-onset dementia as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Chlorpheniramine (CPM) in India, exploring its H1-receptor mechanism, its role in cough syrup 'cocktails', Jan Aushadhi pricing, and the risk of paradoxical excitation as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Hydroxyzine (Atarax) in India, exploring its H1 and dopamine mechanism, its role in opioid withdrawal management, Jan Aushadhi pricing, and the risk of QT prolongation as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Trihexyphenidyl (Pacitane) in India, exploring its anticholinergic mechanism, its misuse as a deliriant (the 'Five-Star' high), Jan Aushadhi pricing, and the risk of cognitive collapse as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Atropine in India, exploring its muscarinic antagonism, its life-saving role in pesticide poisoning, Jan Aushadhi pricing, and the risk of anticholinergic toxicity as of 2026.
GeneralAn exhaustive clinical guide to Morphine in India, covering its history from the British era to its current status as an Essential Narcotic Drug, pricing, pharmacology, and harm-reduction strategies as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Scopolamine (Hyoscine) in India, exploring its amnesic properties, its reputation as the 'Devil's Breath', Jan Aushadhi pricing, and the 2026 crackdown on its illicit use in traveler scams.
GeneralA comprehensive clinical and harm-reduction guide to Amitriptyline (Tryptomer) in India, exploring its role in chronic pain, the narrow therapeutic index, Jan Aushadhi pricing, and the risk of fatal cardiac arrhythmias in 2026.
General